Berenberg Bank Reiterates Buy Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by investment analysts at Berenberg Bank in a research report issued on Wednesday, MarketBeat reports. They currently have a GBX 140 ($1.81) price target on the biopharmaceutical company’s stock. Berenberg Bank’s price target would suggest a potential downside of 98.75% from the stock’s previous close.

Several other equities analysts have also weighed in on AZN. Shore Capital restated a “buy” rating on shares of AstraZeneca in a report on Friday, March 7th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a research note on Wednesday, February 19th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, AstraZeneca currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 7,542.80 ($97.65).

AstraZeneca Stock Performance

Shares of AZN stock opened at £111.96 ($144.95) on Wednesday. The firm has a market cap of £215.41 billion, a P/E ratio of 30.69, a PEG ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. AstraZeneca has a fifty-two week low of GBX 9,670 ($125.19) and a fifty-two week high of £133.88 ($173.33). The stock’s 50-day moving average is £115.78 and its two-hundred day moving average is £112.80.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.